(Date:5/9/2008)...rst Medication Indicated for Maintenance Treatment...all/ -- Eli Lilly and Company,(NYSE: LLY ) announ...inistration (FDA) has approved Strattera(R) (atomo...-Deficit/Hyperactivity Disorder (ADHD) in,children...hrine reuptake,inhibitor, is the first FDA-approve...
(Date:5/9/2008)...NGELES, May 9 /PRNewswire/ -- Los Angeles based Op...n Asia to assess the needs of what is now,an estim...ne which,destroyed or devastated wide swaths of My...ormerly the capital Rangoon) and throughout its va... of over 120 miles per hour and,struck communities...
(Date:5/9/2008)...tion for Iraq and Afghanistan Veterans Gather in V...eterans Service Organizations,, CHANTILLY, Va....raq,enters its fifth year and the U.S. death toll ...he 30,000 mark, a diverse coalition of military,an...have organized to help,bereaved families and wound...
(Date:5/9/2008)...ual demands reap mental benefits regardless of age...ay 9 (HealthDay News) -- Having an intellectually ... result in better cognitive abilities during retir... or age, a Duke University Medical Center study su...work longer than previous generations, so we sough...
Breaking Medicine News(10 mins):Health News:FDA Approves Strattera(R) for Maintenance of ADHD in Children and Adolescents 2Health News:FDA Approves Strattera(R) for Maintenance of ADHD in Children and Adolescents 3Health News:FDA Approves Strattera(R) for Maintenance of ADHD in Children and Adolescents 4Health News:FDA Approves Strattera(R) for Maintenance of ADHD in Children and Adolescents 5Health News:FDA Approves Strattera(R) for Maintenance of ADHD in Children and Adolescents 6Health News:Los Angeles Based Operation USA Appeals for Funds to Aid in Myanmar (Burmese) Cyclone Disaster (Updated) 2Health News:Leading Veterans Service Organizations Meet Near Washington May 13-15, 2008 2Health News:Leading Veterans Service Organizations Meet Near Washington May 13-15, 2008 3Health News:Leading Veterans Service Organizations Meet Near Washington May 13-15, 2008 4Health News:Demanding Jobs May Pay Cognitive Dividends in Retirement 2(Date:5/9/2008)... , TAMPA, Fla., May 9 /PRNewswire-USNewswire/ -- ...tating condition that affects almost 50,million pe...ration of,cartilage in bone joints. The novel inve...y acting oral analgesic, provided significant reli...to those treated with,placebo, and with fewer gast...
(Date:5/9/2008)... SAN DIEGO, May 9 /- Ar...focused on the discovery and development of,small-...ancer and,inflammatory diseases, including gout, t...d Senior Vice President, Finance and Operations an...He will resign from our board of,directors shortly...
(Date:5/8/2008)... CLEVELAND, May 8 /- DA...hnology and services company focused on global,eCl... today reported its,operating results for the firs...rch 31, 2008, revenue decreased,approximately 41% ...of,$(2,233,000), or $(0.16) per share on both a ba...
(Date:5/8/2008)... Efficacy and safety data support potential of ase...phrenia and bipolar I disorder, WASHINGTON, May 8...tion,(NYSE: SGP ) today announced that an overvie...ogram was presented at the 161st Annual Meeting of...n, D.C., May 3-8. Data from,the studies, involving...
Breaking Medicine Technology:Results of Phase 3 Study Show Tapentadol IR Relieves Acute Pain and Offers Favorable Gastrointestinal Tolerability Profile 2Results of Phase 3 Study Show Tapentadol IR Relieves Acute Pain and Offers Favorable Gastrointestinal Tolerability Profile 3Results of Phase 3 Study Show Tapentadol IR Relieves Acute Pain and Offers Favorable Gastrointestinal Tolerability Profile 4Results of Phase 3 Study Show Tapentadol IR Relieves Acute Pain and Offers Favorable Gastrointestinal Tolerability Profile 5Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results 2Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results 3Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results 4Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results 5Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results 6DATATRAK International Reports First Quarter Results for 2008 2DATATRAK International Reports First Quarter Results for 2008 3DATATRAK International Reports First Quarter Results for 2008 4DATATRAK International Reports First Quarter Results for 2008 5DATATRAK International Reports First Quarter Results for 2008 6DATATRAK International Reports First Quarter Results for 2008 7Overview of Asenapine Data from Olympia Trial Program Presented at American Psychiatric Association Annual Meeting 2Overview of Asenapine Data from Olympia Trial Program Presented at American Psychiatric Association Annual Meeting 3Overview of Asenapine Data from Olympia Trial Program Presented at American Psychiatric Association Annual Meeting 4Overview of Asenapine Data from Olympia Trial Program Presented at American Psychiatric Association Annual Meeting 5Overview of Asenapine Data from Olympia Trial Program Presented at American Psychiatric Association Annual Meeting 6Overview of Asenapine Data from Olympia Trial Program Presented at American Psychiatric Association Annual Meeting 7CIDM Collaborates With World Congress to Advance Dialog on Online Provider Networks at WHIT 3 0 3857 1CIDM Collaborates With World Congress to Advance Dialog on Online Provider Networks at WHIT 3 0 3857 2Ohio Delegation Members Urge Colleagues to Vote for Override of SCHIP Veto 3854 1Ohio Delegation Members Urge Colleagues to Vote for Override of SCHIP Veto 3854 2Osteotech Completes Tissue Supply Agreement With LifeNet Health 3851 1Osteotech Completes Tissue Supply Agreement With LifeNet Health 3851 2Getting light to bend backwards 3849 1...ewswire/ -- A nationally renowned,cancer researche...,presented a novel study design concept called a C...elerate new agent development.,Studies utilizing t...he network,s innovative Translational Oncology Pro...y phase trials in a community,setting. These types...
...WIRE)--Jun 5, 2007 - Synta,Pharmaceuticals Corp., ... on discovering, developing, and commercializing s...ions, today announced,it will hold a conference ca...ts, which will be presented at the annual meeting ...) in Chicago, Illinois,this morning., The conferen...
Other Medicine Technology:Study Shows Advantages of Complete Phase Ib Trial Over Separate,Phase I Trials 2Study Shows Advantages of Complete Phase Ib Trial Over Separate,Phase I Trials 3Study Shows Advantages of Complete Phase Ib Trial Over Separate,Phase I Trials 4Study Shows Advantages of Complete Phase Ib Trial Over Separate,Phase I Trials 5300XL System, English (U.K. cord), 100-240 VAC.
The Twin Beam lightsource is a standard light source. The Twin Beam contains two 150W, DNF lamps, one primary lamp, the other to serve as a built-in spare lamp. This allows rapid change to the spare
This single lamp light source is perfect for surgeon's offices, cath labs, dermatology offices, and specialty uses.
A three lamp light source maximizes use by allowing two surgeons to work simultaneously from it, while the third lamp is reserved for backup.
Medicine Products: